Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyCarolina Behavioral Hyperhidrosis Coverage | OpenP…
    Ask Trek AI about this page
    CurrentCarolina Behavioral HealthPolicy NC.CP.MP.62

    Hyperhidrosis Treatments

    Customize your policy alerts

    Sign up for carolinabehavioralhealth Policy NC.CP.MP.62 alerts

    Get alerted when Policy NC.CP.MP.62 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and coverage criteria for iontophoresis, axillary sweat-gland excision, endoscopic thoracic sympathectomy, and other treatments for hyperhidrosis. It applies to members and enrollees of the applicable health plans.

    Policy Summary
    PayerCarolina Behavioral Health
    PolicyHyperhidrosis Treatments
    Policy CodePolicy NC.CP.MP.62
    Change TypeAdministrative annual review
    Effective DateN/A
    Next Review DateN/A
    Key ActionConfirm that iontophoresis requests meet all medical-necessity criteria, including primary hyperhidrosis, significant clinical impact, failed conservative management, and no listed contraindications.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Treatment categories with criteria
    5Iontophoresis contraindications

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >55 bpm
    ETS resting heart rate
    <28ETS BMI requirement
    Insufficient evidenceOther treatments

    Medical Necessity and Coverage Criteria

    Iontophoresis

    Covered as medically necessary when ALL of the following are met:

    Iontophoresis criteria

    • Diagnosis: The member has a diagnosis of primary hyperhidrosis.
    • Clinical impact: The member has medical complications, such as skin maceration with secondary skin infections, or significant constant disruption of professional and/or social life caused by excessive sweating.

      Examples include recurrent changing of clothes or effects on job or social function.

    • Conservative management failure: The member has failed a trial of conservative management, including adherent application of prescription aluminum chloride hexahydrate (Drysol), or topical agents have resulted in a severe rash.
    • No contraindications: The member has none of the following contraindications: cardiac pacemaker, cardiac arrhythmias, pregnancy, metal implants depending on size and position, or epilepsy.

      Metal implants may divert the electric current.

    Surgical excision of axillary sweat glands

    Covered as medically necessary when ALL of the following are met:

    Axillary sweat-gland excision criteria

    • Iontophoresis criteria: The member meets all iontophoresis criteria, including criteria I.A through I.D.
    • Severity: The member has persistent and severe primary hyperhidrosis.
    • Botulinum toxin failure: The member has failed a trial of botulinum toxin.

    Endoscopic thoracic sympathectomy

    Covered as medically necessary when ALL of the following are met:

    Endoscopic thoracic sympathectomy criteria

    • Iontophoresis criteria: The member meets all iontophoresis criteria, including criteria I.A through I.D.
    • Resting heart rate: The member has a resting heart rate greater than 55 beats per minute.> 55 beats per minute
    • Age and symptom onset: Hyperhidrosis symptoms started at an early age, usually before age 16, and surgery is requested for a young member, usually younger than 25 years of age.Symptoms usually started before age 16; surgery usually requested before age 25

    Other treatments with insufficient evidence

    Not covered or unsupported because evidence is insufficient:

    Other hyperhidrosis treatments: Published peer-reviewed literature is insufficient to support other treatments for hyperhidrosis.

    This includes, but is not limited to, microwave therapy and liposuction as the sole method of removing axillary sweat glands.

    Microwave therapy and liposuction as the sole method of removing axillary sweat glands are included among treatments for which the policy finds insufficient evidence.

    Other treatments for hyperhidrosis are not supported as medically necessary when published peer-reviewed evidence is insufficient.

    Coding and Clinical Thresholds

    CPT CodesCPT
    11450Excision of skin and subcutaneous tissue for hidradenitis, axillary; with simple or intermediate repair.
    11451Excision of skin and subcutaneous tissue for hidradenitis, axillary; with complex repair.
    15877*Suction assisted lipectomy; trunk.
    15878*Suction assisted lipectomy; upper extremity.
    32664Thoracoscopy, surgical; with thoracic sympathectomy.
    97024*Application of a modality to 1 or more areas; diathermy (eg, microwave).
    97033Application of a modality to 1 or more areas; iontophoresis, each 15 minutes.
    ETS resting heart rate
    ProcedureEndoscopic thoracic sympathectomy (ETS)
    Applicable hyperhidrosisPalmar or palmar and axillary hyperhidrosis
    Resting heart-rate requirement> 55 beats per minute
    ETS body mass index
    ProcedureEndoscopic thoracic sympathectomy (ETS)
    Applicable hyperhidrosisPalmar or palmar and axillary hyperhidrosis
    Body mass index requirement

    Provider Documentation and Decision Rules

    Documentation Required

    Iontophoresis Medical-Necessity Criteria

    Iontophoresis (electrophoresis, including a Drionic device) is medically necessary only when all of the following requirements are documented: primary hyperhidrosis; medically significant complications or constant disruption of professional and/or social life; failed conservative management or severe rash from topical agents; and no listed contraindication.

    • Diagnosis of primary hyperhidrosis.
    • Medical complications such as skin maceration with secondary skin infections, or significant constant disruption of professional and/or social life due to excessive sweating (for example, recurrent clothing changes or impaired job/social function).
    • Failed a trial of conservative management, including adherent application of prescription aluminum chloride hexahydrate (Drysol), or topical agents caused a severe rash.
    • No cardiac pacemaker, cardiac arrhythmias, pregnancy, disqualifying metal implants based on size and position, or epilepsy.
    Denial Risk

    Condition Overview

    Hyperhidrosis is excessive sweating beyond the level required to maintain normal body temperature. Primary focal hyperhidrosis is idiopathic and associated with sympathetic hyperactivity in selected areas, commonly the axillae, palms, and feet; it may cause clothing damage, emotional distress, and occupational disability. Secondary hyperhidrosis may result from medications or underlying conditions and is usually generalized or craniofacial, so treatment focuses on addressing the underlying cause.

    Definitions

    Hyperhidrosis
    DefinitionExcessive sweating beyond a level required to maintain normal body temperature.
    ClassificationMay be classified as primary or secondary.
    Clinical subjectHyperhidrosis treatments
    Primary focal hyperhidrosis
    CauseIdiopathic excessive sweating induced by sympathetic hyperactivity.
    DistributionOccurs in selected areas, commonly the underarms, hands, and feet.
    Underlying diseaseNot associated with an underlying disease process.
    Policy Summary
    PayerCarolina Behavioral Health
    PolicyHyperhidrosis Treatments
    Policy CodePolicy NC.CP.MP.62
    Change TypeAdministrative annual review
    Effective DateN/A
    Next Review DateN/A
    Key ActionConfirm that iontophoresis requests meet all medical-necessity criteria, including primary hyperhidrosis, significant clinical impact, failed conservative management, and no listed contraindications.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCoding and Clinical ThresholdsProvider Documentation and Decision RulesCondition OverviewDefinitions
    Body mass index: The member's body mass index is less than 28.< 28
  1. Sleep sweating: The member reports no sweating during sleep.
  2. Comorbidities: The member has no significant comorbidities.
  3. Severity: The member has persistent and severe primary hyperhidrosis.
  4. Prior treatment failure: The member has failed iontophoresis or a trial of botulinum toxin for predominantly axillary hyperhidrosis.
  5. Risk counseling: The member has been counseled on the risks of the procedure.
  6. < 28
    ETS symptom onset and age
    ProcedureEndoscopic thoracic sympathectomy (ETS)
    Usual symptom onsetBefore age 16
    Usual age at surgery requestYounger than 25 years of age

    Iontophoresis Criteria Not Met

    Iontophoresis is at denial risk when the record does not establish every medical-necessity element or documents a contraindication.

    • No documented diagnosis of primary hyperhidrosis.
    • No medical complication or significant constant professional/social disruption caused by excessive sweating.
    • No documented failure of conservative management, including prescription aluminum chloride hexahydrate, and no documented severe rash from topical agents.
    • Presence of a cardiac pacemaker, cardiac arrhythmia, pregnancy, disqualifying metal implant, or epilepsy.
    Step Therapy

    Conservative Therapy Before Iontophoresis

    Before iontophoresis, document conservative treatment failure or intolerance, including an adherent trial of prescription aluminum chloride hexahydrate (Drysol).

    • Record the duration, adherence, response, and outcome of the prescription Drysol trial.
    • If topical agents were not tolerated, document the severe rash and the agent(s) used.
    • Iontophoresis remains at denial risk when conservative management was not attempted, adherence is not documented, or the record does not establish a severe topical-agent reaction.
    Documentation Required

    Axillary Sweat-Gland Excision Criteria

    Axillary sweat-gland excision is medically necessary only when all qualifying conditions are documented, including the complete iontophoresis criteria.

    • Meets all iontophoresis criteria: primary hyperhidrosis; medical complications or significant constant professional/social disruption; failed conservative management or severe rash from topical agents; and no contraindication.
    • Persistent and severe primary axillary hyperhidrosis.
    • Failed a trial of botulinum toxin.
    Step Therapy

    Botulinum Toxin Before Gland Excision

    Document a failed botulinum toxin trial before requesting axillary sweat-gland excision.

    • Include the botulinum toxin treatment date(s), treated areas, response, duration of benefit, and reason the trial was considered unsuccessful.
    • Excision is at denial risk when a botulinum toxin trial was not attempted or failure is not documented.
    Documentation Required

    ETS Medical-Necessity Criteria

    Endoscopic thoracic sympathectomy (ETS) for palmar or palmar-and-axillary hyperhidrosis is medically necessary only when all of the following conditions are documented.

    • Meets all iontophoresis criteria, including primary hyperhidrosis, significant complications or professional/social disruption, failed conservative management or severe topical-agent rash, and no contraindication.
    • Resting heart rate is > 55 beats per minute.
    • Symptoms began at an early age, usually < 16 years, and surgery is requested for a young member/enrollee, usually < 25 years of age.
    • Body mass index is < 28.
    • Reports no sweating during sleep.
    • Has no significant comorbidities.
    • Has persistent and severe primary hyperhidrosis.
    • Has failed iontophoresis, or has failed a trial of botulinum toxin when hyperhidrosis is predominantly axillary.
    • Has been counseled on procedure risks.

    Unsupported block type: step_therapy

    Denial Risk

    ETS Criteria Not Met

    ETS is at denial risk when any required clinical threshold, prerequisite, or counseling requirement is absent or not met.

    • Does not meet all iontophoresis criteria or has a contraindication, including a cardiac pacemaker, cardiac arrhythmia, pregnancy, disqualifying metal implant, or epilepsy.
    • Resting heart rate is ≤ 55 beats per minute.
    • Symptoms did not begin at an early age, the surgery request is not for a typically young member/enrollee, or the applicable age documentation is absent.
    • Body mass index is ≥ 28; sweating occurs during sleep; or significant comorbidities are present.
    • Hyperhidrosis is not persistent and severe primary disease.
    • Required prior treatment failed to be attempted or documented: iontophoresis for palmar/palmar-and-axillary disease, or botulinum toxin for predominantly axillary disease.
    • Procedure-risk counseling is not documented.
    Denial Risk

    Insufficient Evidence for Other Treatments

    Other hyperhidrosis treatments are at denial risk because the policy states that published peer-reviewed evidence is insufficient to support them.

    • This includes, but is not limited to, microwave therapy and liposuction as the sole method of removing axillary sweat glands.
    • Coverage should not be presumed for treatments lacking sufficient published peer-reviewed evidence.
    Secondary hyperhidrosis
    CauseMay result from medications or underlying diseases or conditions.
    Usual distributionUsually generalized or craniofacial sweating.
    Examples of causesTricyclic antidepressants, selective serotonin reuptake inhibitors, febrile diseases, diabetes mellitus, or menopause.
    Endoscopic thoracic sympathectomy
    Procedure typeAn invasive procedure intended to arrest the symptoms of hyperhidrosis.
    Anatomic targetThe upper thoracic sympathetic chain.
    Methods used to interrupt the chainClipping, cauterization, or cutting.